We are live on ! Find out more

Bluejay Diagnostics

BJDX

Market cap $841K

0.8125 USD

-0.0351

4.14%

At close Updated Sep 16, 4:00 PM EDT

Pre-market

After hours

0.8287

+0.0162

1.99%

1 day

-4.14%

5 days

-16.24%

1 month

-20.34%

3 months

-82.1%

6 months

-58.33%

Year to date

-68.99%

1 year

-86.72%

5 years

-100%

10 years

-100%

About: Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.

Employees: 6

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets

Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare Channels Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare Channels

Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

ACTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes in critical care settings, today reported financial results for the quarter ended June 30, 2026 and provided an update on the Company's clinical, regulatory and manufacturing progress.

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

750 Patients Enrolled Ahead of Plan in Pivotal Study Evaluating Symphony™ IL-6 for Early Assessment of 28-Day Sepsis Mortality Risk 750 Patients Enrolled Ahead of Plan in Pivotal Study Evaluating Symphony™ IL-6 for Early Assessment of 28-Day Sepsis Mortality Risk

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

What's Going On With Bluejay Diagnostics Shares On Wednesday?

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) shares are trading lower on Wednesday. On Tuesday, the company disclosed a private placement that aims to raise up to $23.6 million.

What's Going On With Bluejay Diagnostics Shares On Wednesday?

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

$8.5 million upfront with up to approximately $15.1 million of potential additional gross proceeds upon the exercise in full of warrants

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

ACTON, Mass. and CARLSBAD, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”) (NASDAQ: BJDX), a medical diagnostics company focused on near-patient testing for critical care, today announced a strategic partnership with Argonaut Manufacturing Services (“Argonaut”) to support the advancement of Bluejay's Symphony™ platform.

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

ACTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes in critical care settings, today provided a corporate update highlighting progress achieved during the first quarter of 2026 and recent operational developments related to its Symphony™ near-patient diagnostic platform.

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

ACTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”), a medical diagnostics company focused on rapid, near-patient testing, today announced the successful enrollment of 624 patients in its ongoing SYMON-II Trial, a pivotal clinical study evaluating the Company's Symphony™ platform for interleukin-6 (IL-6) testing in critical care settings to determine patient acuity for sepsis triage and monitoring.

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented. New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented.

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

See News Rankings

Price charts implemented using Lightweight Charts™